Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-10

As others have already stated ...Financials are very strong ... $151 million so likely 4+ years (not including future R&D grants, and deals of course).

Vaxinia on track, not a single 'hiccup' as we move up the dosing levels, admin methods and also into combo with 'you know who'. Prior to any deals, or the release of total confirmation of CF33 efficacy across multi hard tumours, you actually could not ask for a better 4C release.

It makes it clear to this poster then, that the SP is being 'capped' ... and I can only think of one good reason ... big players like what they see and they 'want in' as cheaply as they can get it.

As many here believe, with the release of the 'total confirmation of CF33 efficacy' (the data), the SP will no longer be able to be 'held back'.
In my humble opinion, as stated several times before, this could be very, very soon.

Not advice of course, just the opinion of one poster.